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Abstract
Objective: To evaluate the benefits and harms of aspirin for the primary prevention of CVD and determine whether the
effects vary by sex and diabetes status.
Methods: We searched Medline, Embase, and Cochrane databases for randomized controlled trials comparing the effects of
aspirin with placebo or control in people with no pre-existing CVD. Two investigators independently extracted data and
assessed the study quality. Analyses were performed using Stata version 12.
Results: Fourteen trials (107,686 participants) were eligible. Aspirin was associated with reductions in major cardiovascular
events (risk ratio, 0.90; 95% confidence interval, 0.85–0.95), myocardial infarction (0.86; 0.75–0.93), ischemic stroke (0.86;
0.75–0.98) and all-cause mortality (0.94; 0.89–0.99). There were also increases in hemorrhagic stroke (1.34; 1.01–1.79) and
major bleeding (1.55; 1.35–1.78) with aspirin. The number needed to treat to prevent 1 major cardiovascular event over a
mean follow-up of 6.8 years was 284. By comparison, the numbers needed to harm to cause 1 major bleeding is 299. In
subgroup analyses, pooled results demonstrated a reduction in myocardial infarction among men (0.71; 0.59–0.85) and
ischemic stroke among women (0.77; 0.63–0.93). Aspirin use was associated with a reduction (0.65; 0.51–0.82) in myocardial
infarction among diabetic men. In meta-regression analyses, the results suggested that aspirin therapy might be associated
with a decrease in stroke among diabetic women and a decrease in MI among diabetic men and risk reductions achieved
with low doses (75 mg/day) were as large as those obtained with higher doses (650 mg/day).
Conclusions: The use of low-dose aspirin was beneficial for primary prevention of CVD and the decision regarding an aspirin
regimen should be made on an individual patient basis. The effects of aspirin therapy varied by sex and diabetes status. A
clear benefit of aspirin in the primary prevention of CVD in people with diabetes needs more trials.
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Introduction
The burden of cardiovascular disease (CVD) is substantial. The
most recent (2013) statistics on heart disease and stroke from the
American Heart Association (AHA) estimate that the annual direct
and indirect cost of CVD and stroke in the United States alone are
$523 billion [1]. From 2000 to 2010, the total number of inpatient
cardiovascular operations and procedures increased 28%, from
5,939,000 to 7,588,000. By 2030, 40.8% of the US population is
projected to have some form of CVD, and the annual cost will
increase to $1.13 trillion [1]. These strong upward trends
underline the importance of primary prevention for those who
are already at high risk of CVD.
The use of low-dose aspirin for primary prevention of CVD is
recommended by many key guidelines [2,3]. However, a recent
published study and a review [4,5] stated that the benefit of aspirin
for the primary prevention of cardiovascular events was relatively
small for individuals regardless of diabetic status and could easily
be offset by the risk of hemorrhage. These studies challenge
current recommendations, which are based on outcomes from
several meta-analyses [6–10], prompting re-evaluation of the
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e90286efficacy of aspirin. An important sex-specific meta-analysis showed
that the effects of aspirin varied by sex [6]. However, it was
conducted in 2006 and included only six primary prevention trials.
In addition, the results were not confirmed in the Antithrombotic
Trialists’ Collaboration meta-analysis and a recent publication
which did not find significant sex different in treatment effect
[7,11]. Several guidelines [12,13] recommend aspirin for the
primary prevention of cardiovascular events in patients with
diabetes at risk of CVD, but others [2,14] do not. This conflict
reflects the lack of definitive evidence. Existing recommendations
are primarily based on extrapolations from indirect evidence,
given the absence of statistically significant results in published
meta-analyses in diabetics [15–23].
Therefore, we performed a new meta-analysis to re-assess the
effects of aspirin for primary prevention of CVD and to investigate
whether the effects vary by sex and diabetes status. Compared to
the previous sex-specific meta-analyses, we enrolled almost twice
that of previously published data. Given the limited power to
detect interactions, even in a meta-analysis combining the results
from several studies [24], we used multiple statistical methods to
examine the diabetes-aspirin interaction and sex-aspirin interac-
tion and their consistent results strengthen our conclusions.
Methods
For this meta-analysis, we used methods and definitions from
previous meta-analyses [6] and performed our meta-analysis in
line with approach recommended by the PRISMA statement [25].
Full study protocol is provided as Text S1.
Data Sources and Searches
Randomized controlled trials (RCTs) comparing the effect of
aspirin with placebo or control in people without pre-existing CVD
on outcomes of interest were eligible for inclusion. We identified
trials by searching Medline, Embase, and Central (the Cochrane
Central Register of Controlled Trials) from inception to December
2012. Reference lists from previously published relevant systematic
reviews were also screened for additional studies [6,8,15]. The
search strategies are as follows: First we searched terms ‘‘aspirin*’’
[MeSH] and term ‘‘primary prevention’’. Then the Boolean term
‘‘AND’’ was used to combine these two terms. Highly sensitive
filters were used to limit results to randomized controlled trials and
human studies. We searched only studies published in English. A
similar search strategy was used for Embase and Central.
Study Selection
Two authors independently reviewed search results by title and
abstract, then full text to identify eligible trials. Selection criteria
included: (1) Prospective, randomized, controlled, open, or blinded
trials. (2) Participants without clinical CVD (e.g., established or
symptomatic) were randomly assigned to aspirin (any dose) versus
placebo or control group for the primary prevention of CVD. (3)
Trials carried out on a background of anticoagulation were
eligible. (4) Follow-up had to exceed 90 days, because such short
follow-up would not permit detection of cardiovascular outcomes
related to aspirin treatment for primary prevention.
Outcomes
The outcomes of interest for both aspirin and control groups
included major cardiovascular events (MCE, defined as death
from cardiovascular causes, nonfatal myocardial infarction, and
nonfatal stroke); myocardial infarction (MI, fatal and nonfatal);
stroke (fatal and nonfatal; ischemic and hemorrhagic); ischemic
stroke; cardiovascular mortality; total mortality (death from any
cause); hemorrhagic stroke and major bleeding. Definitions for
major bleeding varied across studies. However, participant-level
data was unavailable to allow reclassification according to
standard criteria [26–28]. Among all bleeding events, the
gastrointestinal hemorrhage is one of the most common and
serious complications of long-term aspirin use.
Data Extraction and Quality Assessment
Two investigators independently extracted data and evaluated
the methodological quality using criteria previously published
[29]. An arbitrator settled discrepancies by discussion in accor-
dance with our selection criteria. We collected some basic
information on the studies and outcomes of interest listed above.
Data were collected from the original articles, previously published
meta-analyses, and through contact with study authors.
Data Synthesis and Analysis
Analyses were performed using Stata version 12 (Stata Corp).
Heterogeneity was assessed by Cochran’s Q-test and the I
2 statistic
[30]. A P value less than 0.10 indicated significant heterogeneity.
For the I
2 metric, we defined low, moderate, and high I
2 values as
25%, 50%, and 75%, respectively [31]. We estimated the results
with pooled relative risks (RR) and 95% confidence intervals (CI)
using a Mantel-Haenszel fixed-effect model when the heteroge-
neity was negligible or moderate and a DerSimonian and Laird
random-effects model when heterogeneity was significant [32]. All
analyses were based on the intension-to-treat principle. A 2-tailed
P-value 0.05 was considered statistically significant.
To explore potential sources of heterogeneity, we collected
sufficient information to conduct particular subgroup analyses to
determine the sex-aspirin interaction and diabetes-aspirin inter-
action. Because there is limited power to detect interactions, even
in a meta-analysis combining the results from several studies, and
it is not sufficient to conclude that the relative risks from the
subgroups significantly different from each other when the two
estimates and P values seem very different [24]. Thus, we
implemented two methods to determine whether a difference
exists in subgroup analysis. First, we estimated the pooled ratio of
RRs comparing the aspirin effect in patients with and without
diabetes and in patients with different genders across trials.
Second, we used the method of Altman and Bland to compare the
pooled RR and its 95% CI across subgroups [24]. In addition, we
calculated numbers needed to treat (NNT) and numbers needed to
harm (NNH) to examine the risk vs. benefit of aspirin therapy for
some endpoints [33]. Values of NNT and NNH provided herein
represent the number of persons that need to be treated with
aspirin for 6.8 years (the overall mean follow-up time in our study)
to avert or incur, respectively, 1 event.
We also performed meta-regression analyses to appraise the
impact of gender and the daily dose of aspirin on outcomes [34].
Publication bias was assessed by the funnel plot and the Begg’s and
Egger’s tests. We performed a sensitivity analysis to examine the
robustness of the results, systematically removing one study from
the analysis and recalculating the results.
Results
Description of Trials
Details of the included studies appear in Table 1. Table S1
outlines the baseline characteristics and the interventions of the
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ized controlled trials comprised 107, 686 participants for inclusion
from 373 potentially eligible studies (Figure 1). A total of 734,170
person-years of exposure were recorded: 372757 in the aspirin
group and 361413 in the placebo or control group. Specifically,
three trials included apparently healthy health care professionals
[35,36,43]. Only one of the 14 studies included a small proportion
(,10%) of participants with pre-existing established cardiovascu-
lar events [37]. In addition, few studies have populations with high
prevalence of CVD risk factors, e.g., hypertension [40], polycy-
themia vera [42], and peripheral arterial disease [44].
Risk of Bias in Individual Trials
The risk of bias in trials is presented in Table S2. Random-
ization was stated in all studies, but the allocation concealment was
adequately described in only eight studies and unclear in the
remainder. Two trials were open-labeled [41,47], and placebo
tables were not used in the control group in one trial [35].
Outcome assessment was not blinded in one trial [35] and unclear
in two [42,45]. The description of incomplete outcome data was
not adequate in two trials [36,43]. Three studies had a vitamin
component [41,43,44], one had a beta carotene component [36],
one had a anti-oxidant component [46], and one had a warfarin
component [39].
Clinical Outcomes
Efficacy Data: Major Cardiovascular Events. Aspirin use
was associated with a 10% reduction in MCEs (No. of events/No.
of totals, 2392/54487 vs 2505/52827; RR, 0.90; 95% CI, 0.85 to
0.95; P,0.01; Figure 2, Figure S4-A in File S1). The NNT to
avoid 1 MCE over 6.8 years was 284. There was no significant
heterogeneity among the studies in this analysis (Q=14.17,
P=0.29; I
2=15.3%).
Myocardial Infarction. There was also a 14% reduction in
the risk of MI with aspirin (1258/54675 vs 1388/53011; RR, 0.86;
95% CI, 0.75 to 0.98; P=0.02; Figure 2, Figure S4-B in File S1).
The NNT to avoid 1 MI over 6.8 years was 315. However,
heterogeneity was significant (Q=28.17, P=0.01; I
2=53.9%).
Stroke. There was no reduction in the risk of overall stroke
(856/54371 vs 855/52961; RR, 0.95; 95% CI, 0.87 to 1.05;
P=0.34; Figure 2, Figure S4-C in File S1) and no significant
heterogeneity (Q=14.33, P=0.28; I
2=16.3%). When we exam-
ined stroke subtypes (ischemic and hemorrhagic) from the
available data, we found a 14% reduction (374/42999 vs 427/
41350; RR, 0.86; 95% CI, 0.75 to 0.98; P=0.03; Figure 2, Figure
S4-D in File S1) in the risk of ischemic stroke without significant
heterogeneity (Q=9.60, P=0.30; I
2=16.6%). The NNT to avoid
1 l ischemic stroke over 6.8 years was 614.
All-Cause and Cardiovascular Mortality. Pooled results
demonstrated a 6% reduction in the risk of all-cause mortality
Figure 1. Flow chart of articles selection for this systematic review and meta-analysis.
doi:10.1371/journal.pone.0090286.g001
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PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e90286(2329/54627 vs 2334/52961; RR, 0.94; 95% CI, 0.89 to 0.99;
P=0.03; Figure 2, Figure S4-E in File S1). The NNT to avoid
1all-cause mortality over 6.8 years was 697. The heterogeneity was
not significant (Q=5.87, P=0.92; I
2=0%). However, there was
no reduction in cardiovascular mortality (933/54627 vs 855/
52961; RR, 1.04; 95% CI, 0.86 to 1.25; P=0.69; Figure 2, Figure
S4-F in File S1) and the heterogeneity was significant (Q=32.68,
P,0.01; I
2=63.3%).
Safety Data: Hemorrhagic stroke. Aspirin was associated
with a 34% increase in hemorrhagic stroke (113/42999 vs 79/
41350; RR, 1.34; 95% CI, 1.01 to 1.79; P=0.05; Figure 2, Figure
S4-G in File S1). The NNH to cause 1 hemorrhagic stroke over
6.8 years was 1394. Heterogeneity was not significant (Q=3.89,
P=0.87; I
2=0%).
Major bleeding. Pooled results demonstrated a 55% increase
in the risk of major bleeding (522/54439 vs 329/52722; RR, 1.55;
95% CI, 1.35 to 1.78; P,0.01; Figure 2, Figure S4-H in File S1).
The NNT to cause 1 major bleeding over 6.8 years was 299. In
aggregate, heterogeneity was moderate in this analysis (Q=17.47,
P=0.10; I
2=37.0%).
Subgroup Analysis
The effects of aspirin by gender. Details of the included
studies in the subgroup analyses by sex appear in Table S3.
For the endpoint of MCE, aspirin was associated with a 12%
reduction (879/28575 vs 998/28643; RR, 0.88; 95% CI, 0.81 to
0.96; P=0.01) among women, and a 12% reduction (1368/25426
vs 1394/23688; RR, 0.88; 95% CI, 0.82 to 0.95; P,0.01) among
men, without significant heterogeneity (Table 2).
Pooled results demonstrated a 29% reduction (616/23953 vs
760/22257; RR, 0.71; 95% CI, 0.59 to 0.85; P,0.01; Q=12.86,
P=0.03; I
2=61.1%) in the risk of MI among men and a 23%
reduction (176/21211 vs 230/21248; RR, 0.77; 95% CI, 0.63 to
0.93; P=0.01; Q=0.05, P=0.82; I
2=0%) in the risk of ischemic
stroke among women (Table 2).
For hemorrhagic stroke with aspirin, pooled results demon-
strated no significant increase (51/21211 vs 43/21248; RR, 1.19;
95% CI, 0.79 to 1.77; P=0.41) among women but a 69% increase
(50/17960 vs 25/16247; RR, 1.69; 95% CI, 1.05 to 2.72;
P=0.03) among men (Table 2). There was no significant
heterogeneity among the studies in this analysis.
Aspirin use was also associated with a significant risk of major
bleeding irrespective of sex. Pooled results demonstrated a 55%
increase (183/25648 vs 118/25694; RR, 1.55; 95%CI, 1.23 to
1.96; P,0.01; Q=3.15, P=0.21; I
2=36.6%) among women and
a 79% increase (195/22922 vs 102/21227; RR, 1.79; 95%CI,
1.41 to 2.27; P,0.01; Q=2.27, P=0.69; I
2=0%) among men
(Table 2).
When we used the method of Altman and Bland to compare the
pooled RR and its 95% CI of MI (P=0.02) and stroke (P=0.01),
the results also provide strong support for gender difference in the
reduction of MI and stroke.
The effects of aspirin by diabetes status. Details of the
included studies in the subgroup analyses by diabetes status appear
in Table S4-A and Table S4-B.
The estimate stratified by diabetes status was significant only for
the outcome of MCEs. Pooled results demonstrated a 9%
reduction (1285/35626 vs 1268/34021; RR, 0.91, 95% CI, 0.84
to 0.98, P=0.01) among nondiabetic patients but no significant
reduction among diabetic patients (Table 2). Given that the small
number of the diabetic patients, we stratified the trials by the
percentage of diabetic patients (,50% vs.50%). For trials with
percentage of diabetic patients ,50% and.50%, the RRs of MI
were 0.85 (95% CI 0.72 to 0.99; P=0.04; Q=20.57, P=0.02;
I
2=56.2%) and 0.88 (95% CI,0.65 to 1.20; P=0.42; Q=6.97,
P=0.07; I
2=57.0%) respectively, and the RRs of major bleeding
were 1.67 (95% CI, 1.43 to 1.94; P,0.01; Q=5.78, P=0.57;
I
2=0%) and 1.12 (95% CI, 0.82 to 1.54; P=0.46; Q=5.89,
Figure 2. Effect of aspirin therapy versus placebo or control for primary prevention of CVD. MCE=major cardiovascular events;
MI=myocardial infarction; CVD=cardiovascular disease.
doi:10.1371/journal.pone.0090286.g002
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2=49.1%), respectively (Table 2). When we used the
method of Altman and Bland to compare the pooled RRs and
their 95% CIs of major bleeding (P=0.03), the result demon-
strated different treatment effects in trials according to the
percentage of diabetic patients.
Among diabetic patients, we also conducted stratified analysis
by sex. Pooled results demonstrated a 35% reduction in MI among
men (RR, 0.65; 95% CI, 0.51 to 0.82; P,0.01; Q=3.21,
P=0.20; I
2=37.6%), but the results were not significant in
women (RR, 0.90; 95% CI, 0.71 to 1.14; P=0.37; Q=4.01,
P=0.14; I
2=50.1%). When we used the method of Altman and
Bland to compare the pooled RR and its 95% CI (P=0.06), the
results demonstrated that difference in the reduction of MI was not
significant. The data was insufficient to estimate other endpoints in
diabetic patients.
Meta-regression
First we performed meta-regression in all populations to
appraise the impact of the percentage of males on the incidence
of endpoints. There was a statistically significant relationship
between percentage of males and the effect of aspirin on stroke
(P=0.04) (Figure 3A), which supported the conclusions from
subgroup analysis. With respect to the negative results among
patients with diabetes, we then performed meta-regression in
diabetic patients. The result demonstrated a significant association
between percentage of males and the effects of aspirin on MI
(P=0.03) (Figure 3B) and stroke (P=0.02) (Figure 3C), suggesting
that aspirin therapy might be associated with a decrease in stroke
among diabetic women and a decrease in MI among diabetic men.
We also performed meta-regression to test for a linear relation
of the positive effects (reduction in MCE, MI, ischemic stroke) or
complications (major bleeding and hemorrhagic stroke) with daily
dose of aspirin. The results suggested that risk reductions achieved
with low doses (75 mg/day) were as large as those obtained with
higher doses (650 mg/day), and the risk for bleeding did not
increase with dose (Figure S1).
Sensitivity Analysis
The heterogeneity was significant for the outcome of MI
(Q=28.17, P=0.01; I
2=53.9%), which may be explained by the
fact that WHS enrolled only women (weight 13.61%) and the PHS
enrolled only men (weight 16.86%). The RR was 0.84 and 0.91
when these two studies were respectively removed from the model
(Figure S2). After excluding these two studies from our analyses,
heterogeneity between trials substantially decreased (921/23704 vs
956/22035; RR, 0.88; 95%CI, 0.81 to 0.96; P,0.01, Q=11.14,
P=0.43; I
2=1.3%).
Publication Bias
We used a comprehensive literature search strategy to minimize
the risk of publication bias. Results of Begg’s and Egger’s tests for
asymmetry were not statistically significant (Figure S3).
Discussion
In a comparison of aspirin with placebo or control for the
prevention of CVD, we found significant benefits of 10, 14, and
14% risk reduction for the outcomes of MCEs, MI, and ischemic
stroke respectively in the overall population. Meanwhile, there
were also clear harms of 34% relative increase in hemorrhagic
stroke and 55% relative increase in major bleeding events. Our
subgroup and meta-regression analyses indicated that the effects of
aspirin therapy varied by sex and diabetes status. Aspirin use was
associated with a significant reduction in the risk of cardiovascular
events in both sexes but different specific types of benefits: a
reduction in MI among men and a reduction in ischemic stroke
among women. Aspirin had no significant effect on CVD in the
overall diabetic population, but was associated with a reduction in
MI among men with diabetes.
Although the results indicate a significant increase in bleeding
complications, it is not sensible to conclude that the benefit of
aspirin is offset by the risk of bleeding. First, we should estimate
not only the incidence of benefits and harms, but also take into
account the consequences of both harms and benefits on quality of
life [49]. Setting aside the potentially fatal MI or stroke, it is clear
that a non-fatal stroke or MI is more likely to result in long-term
disability than a non-fatal gastrointestinal or other extracranial
bleed. Although serious intracranial and extracranial bleed may
also cause serious results, our results suggest that the benefit of
reducing risk of ischemic stroke outweigh the harm hemorrhagic
stroke. In addition, there are several methods to mitigate these
adverse effects, for example, clinicians can remind those patients
who decide to begin or continue an aspirin regiment for primary
prevention of CVD, of the early recognition of the signs and
symptoms as well as the risk factors of gastrointestinal bleeding.
These risk factors include age, gender, upper gastrointestinal tract
pain, gastrointestinal ulcers, NSAID use, uncontrolled hyperten-
sion, concomitant use of anticoagulants, and family history of
gastrointestinal ulcers and so on [50].
Figure 3. Meta-regression between male percentage and the effects of aspirin on risk of MI or stroke. (A) Log relative risk of stroke in
relation to male percentage in all people. (B) Log relative risk of MI in relation to male percentage in diabetic patients. (C) Log relative risk of stroke in
relation to male percentage in diabetic patients. The gray bonds in each figure are confidence interval. The size of the bubble represents the value of
the weight. MI=myocardial infarction.
doi:10.1371/journal.pone.0090286.g003
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that few subjects exceeded the threshold for aspirin prophylaxis
recommended by the American Heart Association [51]. In
addition, evidence shows that.60% of aspirin users were above
60 years of age, 4–6% had a recent history of peptic ulcers, and
over 13% used other non-steroidal antiinflammatory drugs [52]. It
is obvious that the gastrointestinal harms would outweigh the
cardiovascular benefits in certain groups whose gastrointestinal
risk is high but cardiovascular risk is low. Thus, some of the
previous published trials may overestimate the harm effect of the
aspirin.
Third, the Antithrombotic Trialists’ Collaborative, an individ-
ual-level meta-analysis of RCTs, indicated that the absolute
benefits of aspirin were on a small order of magnitude in primary
prevention and the effects of aspirin do not significantly depend on
smoking history, blood pressure, total cholesterol, body-mass
index, history of diabetes, or predicted risk of coronary heart
disease [7]. However, the small number and rare events in these
particular subgroups are not sufficient for precise estimate, and
thus this paper provides insufficient evidence to answer the
question of which particular category of individuals derive the
most benefit from aspirin therapy. More highly powered analyses
for specific populations are expected based on two major ongoing
trials: the Aspirin to Reduce Risk of Initial Vascular Events
(ARRIVE) Study (http://www.arrive-study.com/EN/study.cfm)
and Aspirin in Reducing Events in the Elderly (ASPREE) [53].
The results of our subgroup analysis consistent with prior studies
indicate that there is no significant benefit of aspirin therapy
among patients with diabetes, but this may be due to inadequate
power because the point estimate was similar to that among
nondiabetics but with a wider confidence interval. It is well
established that diabetes mellitus is associated with an increased
risk of CVD [54]. Among diabetes patients, the coagulation system
is altered, because plasma levels of procoagulant factors are
increased while fibrinolytic capacity is decreased [55].
The mechanisms of the antithrombotic effects of low-does
aspirin involve two aspects: cyclooxygenase (COX)-dependent
actions and COX-independent actions [56]. Low-dose aspirin is
considered to induce a permanent inactivation of COX-1 which
results in the inhibition of platelet aggregation [57,58]. In many
people, generation of new platelets and recovery of COX-
dependent platelet aggregation can reverse to a certain degree
this effect within 24 hours after administration of aspirin [59].
Thus successive and low-dose daily administration of aspirin is
essential to maintain inactivation of platelet COX-1. However,
patients with type 2 diabetes have been demonstrated to be
characterized by a large inter-individual variability in the recovery
of COX-1 activity and enhanced platelet turnover rate which
represents an important determinant of the extent and duration of
platelet inhibition on repeated dosing with low-dose aspirin [60–
63]. Thus it is possible that the current use of a once-a-day and
low-dose regimen may not be sufficient to induce clinical benefits
among diabetic patients [64–67]. More studies are needed to
demonstrate whether a higher frequency of aspirin administration
and possibly a higher daily dosage can optimize treatment with
aspirin in diabetic patients. In addition, considerable efforts are
needed to illuminate the relation between decreased responsive-
ness to aspirin and the COX-independent antithrombotic effects
[56].
Platelet dysfunction, increased platelet aggregation and aspirin
insensitivity were more common in patients with type 2 diabetes
compared to nondiabetic people [68] [62]. In addition, insulin
resistance and hyperglycaemia are reported to contribute to these
alterations [55]. Among our eligible 14 studies, 6 were published
before 2000. The management and treatments of diabetes have
been improved over the decades. Thus, the treatments of diabetes
are much different between the old studies and recent studies.
These differences of the treatments may have impact on the effect
of aspirin in diabetes subgroup analysis.
Our meta-regression analyses indicate that aspirin therapy may
have different effects between the sexes in diabetic patients.
Although there is no evidence that the pharmacodynamics of
platelet inhibition by aspirin is any different in women than in
men, the overall risk of CVD for people with diabetes is reported
to be increased two-to threefold in men, and three-to fivefold in
women [23]. More highly powered subgroup analyses for specific
populations are awaited based on two major ongoing trials: A
Study of Cardiovascular Events in Diabetes (ASCEND, Interna-
tional Standard Randomised Controlled Trial Number
ISRCTN60635500, http://www.ctsu.ox.ac.uk/ascend/) and the
Aspirin and Simvastatin Combination for Cardiovascular Events
Prevention Trial in Diabetes (ACCEPT-D, Current Controlled
Trials ISRCTN48110081) [69], which enrolled more than 15,000
diabetic patients without prior cardiovascular events to assess the
effect of aspirin in the prevention of cardiovascular events. These
trials may provide sufficient data to identify patients who derive
the most benefit from aspirin therapy.
In sex subgroup analysis, our results are consistent with the
previous sex-specific meta-analysis [6], but our findings conflicted
with a recent publication which did not find any significant sex
different in treatment effect [7,11]. There are several potential
explanations for the different effects between sexes.
First, the different epidemiologic characteristics of cardiovascu-
lar disease between men and women may contribute to the
different benefits. After age 40 years, men have a 49% lifetime risk
for a coronary heart disease event, while women have a 32% risk.
Men have a higher risk for MI, while the lifetime risk for ischemic
stroke is greater in women than men from age 55 to 75 (17–18% in
women and 13–14% in men) [2], and the risk of gastrointestinal
bleeding is approximately twice as high in men than women [50].
Second, although some evidence indicates that there is no
difference in pharmacodynamics of platelet inhibition by aspirin
between the sexes and the ‘aspirin resistance’ may not exist [70–
72], there is still insufficient evidence to support these conclusions.
In fact, few randomized trials have measured ‘aspirin resistance’
directly, whether gender plays an important part in ‘aspirin
resistance’ remains a question for future research [73–76].
The range of the dosage varies from 75 to 650 mg/day in
eligible trials. Our analysis suggests that risk reductions achieved
with low doses (75 mg/day) were similar to those obtained with
higher doses (650 mg/day). In fact, it is reported that the
successive daily administration of 30 mg of aspirin is sufficient to
result in virtually inactivation of COX-1 [77]. However, there is
no trial using this dosage. It is reported that apart from the
inhibition of platelet aggregation, the impairment of cytoprotec-
tion in the gastrointestinal mucosa which is clearly dose-dependent
also increases risk of upper gastrointestinal bleeding associated
with aspirin therapy [72]. Thus, it is very likely that lower dosage
of aspirin would decrease the bleeding complications. There is a
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whether lower dosage of aspirin should be recommended for
primary prevention of CVD in the future. However, because of the
varied definitions of major bleeding among the studies, the result
of our meta-regression does not indicate a clear does-effect relation
which conflicts with previous published studies [78,79].
We acknowledge several limitations of our studies. First, we
observed moderate heterogeneity among trials for some outcomes
of interest. However, we have no access to patient-level data and
our author response rate was relatively low, which may have led to
limited statistical power. Second, the data were insufficient to
report separate outcomes for type 1 and type 2 diabetes and
different sexes in diabetic patients. Finally, the data on bleeding in
our analyses were not sufficient to estimate whether changes in the
dose of aspirin might reduce the risk of hemorrhage and whether
further attempts at dosage reduction may compromise therapeutic
efficacy.
In conclusion, our results demonstrate a significant net benefit
to risk of aspirin for the primary prevention of CVD, and the
decision regarding an aspirin regimen should be made on an
individual patient basis, after careful evaluation of the trade-off
between benefits and harms by the physician and patient. The
effects of aspirin therapy vary by sex. Additional evidence is
necessary before we make specific recommendations for aspirin
use according to diabetes status.
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